Teachers Retirement System of The State of Kentucky Sells 5,100 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Teachers Retirement System of The State of Kentucky trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 4.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 105,326 shares of the biotechnology company’s stock after selling 5,100 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Exelixis were worth $2,527,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of EXEL. Charles Schwab Investment Management Inc. lifted its holdings in Exelixis by 0.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,364,480 shares of the biotechnology company’s stock worth $80,714,000 after buying an additional 28,840 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of Exelixis by 18.5% during the fourth quarter. First Trust Advisors LP now owns 3,152,755 shares of the biotechnology company’s stock valued at $75,635,000 after acquiring an additional 492,613 shares during the period. Norges Bank bought a new position in Exelixis in the fourth quarter valued at about $73,449,000. FMR LLC increased its position in Exelixis by 9.3% in the third quarter. FMR LLC now owns 2,884,424 shares of the biotechnology company’s stock worth $63,025,000 after purchasing an additional 246,605 shares during the period. Finally, Ameriprise Financial Inc. increased its position in Exelixis by 10.7% in the third quarter. Ameriprise Financial Inc. now owns 2,266,932 shares of the biotechnology company’s stock worth $49,489,000 after purchasing an additional 218,757 shares during the period. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Performance

Shares of EXEL opened at $21.73 on Friday. The firm’s 50 day moving average price is $21.92 and its two-hundred day moving average price is $22.34. Exelixis, Inc. has a twelve month low of $18.64 and a twelve month high of $24.34. The firm has a market cap of $6.59 billion, a P/E ratio of 33.69, a PEG ratio of 0.53 and a beta of 0.56.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.16). The company had revenue of $425.23 million during the quarter, compared to the consensus estimate of $461.04 million. Exelixis had a net margin of 11.10% and a return on equity of 8.85%. The company’s revenue was up 4.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.12 earnings per share. On average, sell-side analysts anticipate that Exelixis, Inc. will post 1.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EXEL has been the topic of a number of research reports. Stephens started coverage on shares of Exelixis in a research report on Tuesday, May 14th. They set an “equal weight” rating and a $23.00 target price on the stock. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a report on Wednesday, May 1st. JMP Securities reiterated a “market outperform” rating and set a $27.00 target price on shares of Exelixis in a research report on Wednesday, April 10th. TD Cowen raised their price target on Exelixis from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Exelixis in a research note on Friday, May 3rd. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $26.13.

Insider Transactions at Exelixis

In related news, Director George Poste sold 11,686 shares of Exelixis stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total value of $244,938.56. Following the sale, the director now owns 213,907 shares of the company’s stock, valued at approximately $4,483,490.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Jack L. Wyszomierski sold 8,287 shares of the stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $22.00, for a total transaction of $182,314.00. Following the completion of the transaction, the director now directly owns 349,499 shares in the company, valued at approximately $7,688,978. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director George Poste sold 11,686 shares of Exelixis stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $20.96, for a total value of $244,938.56. Following the completion of the sale, the director now directly owns 213,907 shares in the company, valued at approximately $4,483,490.72. The disclosure for this sale can be found here. Insiders sold 30,896 shares of company stock valued at $660,677 over the last three months. Company insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.